| Literature DB >> 26657223 |
Michael E Ballard1,2, Andy C Dean1,3, Mark A Mandelkern2,4, Edythe D London1,2,3,5.
Abstract
BACKGROUND: Dopamine D2/D3 receptor availability in the striatum has been linked with executive function in healthy individuals, and is below control levels among drug addicts, possibly contributing to diminished executive function in the latter group. This study tested for an association of striatal D2/D3 receptor availability with a measure of executive function among research participants who met DSM-IV criteria for methamphetamine dependence.Entities:
Mesh:
Substances:
Year: 2015 PMID: 26657223 PMCID: PMC4699455 DOI: 10.1371/journal.pone.0143510
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Characteristics of research participants.
| Group | Controls ( | MA users ( |
|---|---|---|
| Sex (M/F) | 11/7 | 10/8 |
| Age (years) | 36.4 ± 9.2 (19–51) | 33.1 ± 7.8 (19–46) |
| Education (years) | 14.3 ± 2.2 (10–18) | 12.6 ± 1.5 (11–16) |
| Ethnicity (White/Hispanic or Latino/Asian/Native American/Other | 11/4/2/1/0 | 11/4/2/0/1 |
| No. daily tobacco smokers (M/F) | 7/4 | 9/5 |
| Cigarettes per day (daily smokers only) | 12.8 ± 4.9 (8–20) | 12.1 ± 11.7 (3–40) |
| Years smoking (daily smokers only) | 17.5 ± 11.4 (3–35) | 17.3 ± 9.6 (3–34) |
| FTND score (daily smokers only) | 3.5 ± 2.3 (0–8) | 3.1 ± 2.8 (0–9) |
| Duration of regular MA use (years) | N/A | 9.3 ± 7.9 (0.5–24) |
| Frequency of MA use (days in last 30 days) | N/A | 21.9 ± 8.7 (5–30) |
| Intensity of MA use (grams in last week) | N/A | 2.8 ± 3.3 (0.3–14.5) |
Data are presented as mean + SD (range), except for sex, ethnicity, and smoking status.
†Other refers to individuals not identifying as White, African American, Hispanic/Latino, Asian, or Native American
FTND: Fagerström Test for Nicotine Dependence (possible range: 0 [low]—10 [high]; [52])
*Significant group difference, p < .05.
Comparison of striatal BPND and WCST performance between MA users and controls (n = 18 each).
| Measure | Means (SEM) | Independent samples | ANOVA with covariates | ||||
|---|---|---|---|---|---|---|---|
| MA users | Controls |
|
|
|
|
| |
| Whole striatum BPND | 17.56 (0.64) | 19.85 (0.93) | 2.03 (34) | 0.050 | 9.49 (1,32) | 0.004 | 0.229 |
| LST BPND | 15.53 (0.54) | 17.45 (0.73) | 2.12 (34) | 0.042 | 10.26 (1,32) | 0.003 | 0.243 |
| AST BPND | 17.41 (0.64) | 19.45 (0.95) | 1.78 (34) | 0.085 | 7.11 (1,32) | 0.012 | 0.182 |
| SMST BPND | 19.44 (0.69) | 21.76 (1.06) | 1.84 (34) | 0.075 | 9.14 (1,32) | 0.005 | 0.222 |
| WCST proportion of | |||||||
| NPEs | 0.10 (0.02) | 0.08 (0.01) | 1.61 (34) | 0.117 | 0.34 (1,33) | 0.566 | 0.010 |
| PEs | 0.12 (0.02) | 0.09 (0.01) | 1.36 (34) | 0.184 | 0.29 (1,33) | 0.592 | 0.009 |
ANOVA covariates are age and years of formal education for BPND analyses, and age for WCST analyses
LST: limbic striatum; AST: associative striatum; SMST: sensorimotor striatum;
NPEs: non-perseverative errors; PEs: perseverative errors.
Fig 1Relationships between striatal D2/D3 receptor availability and executive function measures.
Regression lines illustrate correlations between striatal dopamine D2/D3 receptor availability (indexed by [18F]fallypride BPND) and proportions of trials registered as non-perseverative (top row) and perseverative (bottom row) errors in methamphetamine (MA) users and non-user controls. Pearson product-moment correlation coefficients are shown (r values).
Fig 2Relationships between D2/D3 receptor availability in striatal subregions and executive function measures.
Regression lines illustrate correlations between striatal dopamine D2/D3 receptor availability (indexed by [18F]fallypride BPND) and proportions of trials registered as non-perseverative and perseverative errors in the striatal functional subdivisions of methamphetamine (MA) users (bottom row) and non-user controls (top row). Pearson product-moment correlation coefficients are shown (r values).